Related Experiment Videos
[Antineoplastic chemotherapy for bronchial carcinoma].
Archiv Fur Geschwulstforschung
|January 1, 1985
Summary
Chemotherapy for non-small cell lung cancer remains challenging. However, polychemotherapy offers significant remission rates for small cell lung cancer, with ongoing research into combined treatments.
Area of Science:
- Medical Oncology
- Pulmonology
- Clinical Pharmacology
Context:
- Lung cancer treatment landscape, focusing on non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC).
- Current limitations of chemotherapy in NSCLC, with ongoing investigation of novel agents like Cisplatin, VP16, and Vindesine.
- Established efficacy of polychemotherapy in SCLC, demonstrating superior outcomes compared to monochemotherapy.
Purpose:
- To review and compare the current therapeutic strategies for NSCLC and SCLC.
- To evaluate the effectiveness of various chemotherapy regimens and combinations in achieving tumor remission.
- To highlight the role of radiotherapy in conjunction with chemotherapy for both types of lung cancer.
Summary:
- Chemotherapy for NSCLC yields generally unsatisfactory results, with promising combinations (e.g., Cyclophosphamide/Doxorubicin/Methotrexate/Procarbazine) showing 30-40% remission rates.
- Radiotherapy, potentially combined with chemotherapy, remains the primary treatment for NSCLC.
- Polychemotherapy is highly effective for SCLC, achieving 80% remission in limited cases and 65% in advanced cases, with remissions lasting up to 18 months.
Impact:
- Identifies key chemotherapy combinations and their remission rates for both NSCLC and SCLC.
- Emphasizes the current standard of care, including the continued importance of radiotherapy for NSCLC.
- Suggests future research directions, particularly the investigation of combined modality treatments and prophylactic cranial irradiation for SCLC.